List of Excipients in Branded Drug NUVARING

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Organon USA Inc	NUVARING	etonogestrel and ethinyl estradiol	0052-0273	ETHYLENE-VINYL ACETATE COPOLYMER
Organon USA Inc	NUVARING	etonogestrel and ethinyl estradiol	0052-0273	MAGNESIUM STEARATE
A-S Medication Solutions	NUVARING	etonogestrel and ethinyl estradiol	50090-1008	ETHYLENE-VINYL ACETATE COPOLYMER
A-S Medication Solutions	NUVARING	etonogestrel and ethinyl estradiol	50090-1008	MAGNESIUM STEARATE
A-S Medication Solutions	NUVARING	etonogestrel and ethinyl estradiol	50090-5611	ETHYLENE-VINYL ACETATE COPOLYMER

NuvaRing Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

NuvaRing is a monthly combined hormonal vaginal ring containing etonogestrel and ethinyl estradiol. Its core excipient system is an ethylene-vinyl acetate copolymer matrix with magnesium stearate. The commercial opportunity has shifted from basic generic substitution to differentiated vaginal-ring platforms, formulation engineering, manufacturing capacity, and lifecycle products with longer wear periods or improved user control.

What excipients are used in NuvaRing?

NuvaRing uses a polymeric drug-delivery matrix rather than a conventional tablet or liquid formulation. The ring contains:

Component	Function
Etonogestrel, 11.7 mg	Progestin active ingredient
Ethinyl estradiol, 2.7 mg	Estrogen active ingredient
Ethylene-vinyl acetate copolymer	Matrix-forming excipient and release-control polymer
Magnesium stearate	Processing aid and formulation excipient

The ring has an outer diameter of approximately 54 mm and a cross-sectional diameter of approximately 4 mm. The labeled release rates are approximately 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week in-vivo period.[1]

The formulation is designed to provide diffusion-controlled release through a non-biodegradable polymer matrix. The excipient system determines drug loading, mechanical integrity, residual monomer profile, release-rate stability, and compatibility with vaginal fluids.

How does NuvaRing’s EVA excipient system work?

The active ingredients are dispersed in an ethylene-vinyl acetate copolymer. Drug release occurs as molecules diffuse through the polymer matrix and partition into vaginal fluid.

The critical formulation variables are:

• Vinyl acetate content in the EVA grade.
• Polymer molecular weight and melt-flow characteristics.
• Drug solubility and dispersion within the matrix.
• Ring extrusion temperature and residence time.
• Ring diameter and cross-sectional geometry.
• Surface area exposed during use.
• Drug-polymer compatibility.
• Moisture uptake and storage conditions.
• Residual solvent and volatile content.

EVA is commercially attractive because it is well established in medical devices, thermoplastics, and controlled-release systems. It can be processed by extrusion and supports continuous manufacturing. Its limitations include potential batch-to-batch variation in drug distribution, dependence of release rate on polymer composition, and the need to control thermal exposure during manufacturing.

Magnesium stearate is present at a low level and is primarily relevant to processability and dispersion. It has a smaller strategic impact than the EVA matrix, but changes in grade, particle size, surface area, or concentration can affect blend uniformity and extrusion performance.

What excipient patents protect NuvaRing-type products?

The commercial protection for a NuvaRing-type product is likely to involve several patent layers rather than a single excipient patent:

1. Drug-polymer composition claims. These may cover the combination of etonogestrel and ethinyl estradiol in a polymeric vaginal device.
2. Release-profile claims. Claims may define daily release rates, loading levels, or plasma exposure.
3. Device geometry claims. Ring diameter, cross-sectional dimensions, multilayer construction, and drug-containing segments may be claimed.
4. Manufacturing claims. Extrusion, blending, curing, cutting, and surface-treatment steps can create separate barriers.
5. Method-of-use claims. Patents may cover contraception, menstrual-cycle control, or specific insertion and removal schedules.
6. Packaging claims. Moisture-barrier packaging, temperature control, and storage systems can support lifecycle management.

For a generic applicant, the principal risk is usually not the identity of EVA itself. EVA is a broadly available excipient. The greater risk is whether the applicant’s ring reproduces a protected combination of polymer composition, drug loading, geometry, release profile, or manufacturing process.

The original NuvaRing patent estate has substantially aged because the product was first approved in the United States in 2001. Generic entry has occurred, which indicates that basic product-level barriers were overcome or became commercially manageable. Current freedom-to-operate analysis still requires review of live U.S. and foreign patents, Orange Book listings, terminal disclaimers, and litigation records.[2]

What is the FDA regulatory status of NuvaRing and generic equivalents?

NuvaRing was approved by the FDA under NDA 021187 for prevention of pregnancy.[1] The product is a drug-device combination in which the active pharmaceutical ingredients are delivered through a polymeric vaginal ring.

EluRyng, a generic etonogestrel/ethinyl estradiol vaginal ring, was approved by the FDA in 2019 under ANDA 209457.[3] The generic product uses the same active ingredients and a comparable ring-based delivery concept. Its approval confirmed that an abbreviated pathway could be used for a monthly combined hormonal vaginal ring.

Product	Active ingredients	FDA status	Commercial relevance
NuvaRing	Etonogestrel and ethinyl estradiol	Original NDA product	Reference product and brand benchmark
EluRyng	Etonogestrel and ethinyl estradiol	ANDA-approved generic	Direct generic competitor
Annovera	Segesterone acetate and ethinyl estradiol	NDA-approved reusable ring	Differentiated long-duration competitor

The Orange Book remains the principal source for listed patents and regulatory exclusivity associated with the FDA reference product. For NuvaRing, the commercial landscape is now driven mainly by generic pricing, payer coverage, supply reliability, and product differentiation rather than by a remaining period of new-molecule exclusivity.[2]

When did NuvaRing lose exclusivity?

NuvaRing’s original five-year new chemical entity exclusivity expired years ago. Generic competition reached the U.S. market in 2019 with EluRyng.[3]

The key commercial dates are:

Event	Date
U.S. NuvaRing approval	October 3, 2001
First U.S. generic approval, EluRyng	April 2019
Generic commercialization	2019 onward
Annovera approval	August 2018

The exact timing of generic launch depended on patent certifications, regulatory approval, manufacturing readiness, and commercial decisions by the generic applicant. Generic availability materially reduced the value of the original NuvaRing formulation as a protected product, but it did not eliminate opportunities in improved rings or alternative excipient platforms.

What formulation opportunities exist beyond the original NuvaRing excipients?

Alternative thermoplastic matrices

Potential substitutes for EVA include:

• Polyurethane-based elastomers.
• Silicone-polymer systems.
• Polyethylene and polyolefin blends.
• Thermoplastic medical-grade elastomers.
• Multilayer polymer structures.

A substitute must preserve drug stability, release-rate control, flexibility, vaginal tolerability, and manufacturing reproducibility. A polymer change may create a differentiated product, but it can also trigger extensive comparative release, safety, and extractables testing.

Multilayer and core-shell rings

A multilayer ring can separate the progestin and estrogen or place one active ingredient in a central core. This architecture may improve control over:

• Independent release rates.
• Drug-drug interaction within the matrix.
• Surface burst release.
• Stability during storage.
• Dose adjustment.

Multilayer construction also creates patentable manufacturing and geometry features. The commercial value is highest where the design produces a clinically relevant benefit, such as reduced estrogen exposure or a longer dosing interval.

Bioadhesive or mucoadhesive systems

Mucoadhesive excipients may improve retention, but adhesion creates tradeoffs. A ring that adheres too strongly may be uncomfortable to remove or may alter local tissue exposure. Mucoadhesive systems also require focused evaluation of irritation, microbiome effects, vaginal discharge, and user acceptability.

Biodegradable rings

Biodegradable polymers could eliminate removal and disposal requirements. Candidate materials include polyesters such as poly(lactic-co-glycolic acid), although their degradation products, mechanical behavior, and release kinetics are materially different from EVA.

This approach has higher technical and regulatory risk. The product must control degradation rate, local acidity, polymer fragments, and dose delivery over the full treatment period.

Longer-duration rings

A six-month or annual ring would offer a clear commercial distinction from the monthly NuvaRing model. The main excipient challenge is maintaining a stable low release rate for a prolonged period without excessive initial burst or late-cycle dose decline.

A longer-duration platform could use:

• Higher-capacity drug cores.
• Reservoir designs.
• Multiple drug-loaded segments.
• Low-permeability rate-control membranes.
• Separate estrogen and progestin compartments.

The most attractive formulation opportunity is a longer-duration ring with a clear adherence advantage and a manageable insertion-and-removal procedure.

How does NuvaRing compare with Annovera?

Annovera is a reusable vaginal ring containing segesterone acetate and ethinyl estradiol. It is designed for use for 13 cycles, with the user removing the ring for one week during each cycle.[4]

Attribute	NuvaRing	Annovera
Progestin	Etonogestrel	Segesterone acetate
Estrogen	Ethinyl estradiol	Ethinyl estradiol
Use cycle	Monthly replacement	Reusable for 13 cycles
Polymer approach	EVA matrix	Silicone-based ring technology
Regulatory pathway	Original NDA and generic ANDA	NDA
Primary differentiation	Established monthly ring	Reduced replacement frequency
Main commercial constraint	Generic price competition	Higher product complexity and access

Annovera demonstrates the commercial value of changing the delivery system rather than merely copying the active ingredients. Its reusable design creates new opportunities in polymer selection, dose reservoir engineering, cleaning instructions, packaging, and user adherence.

For an excipient supplier, Annovera-type technology is more attractive than commodity EVA supply because it can require proprietary polymer grades, formulation support, device-scale development, and long-term supply agreements.

What commercial opportunities exist for excipient suppliers?

Medical-grade EVA supply

The most immediate opportunity is supplying validated EVA grades to generic manufacturers and contract development and manufacturing organizations. The supplier must provide:

• Tight vinyl acetate-content specifications.
• Controlled melt flow.
• Low extractables and leachables.
• Consistent residual volatile levels.
• Pharmaceutical-grade documentation.
• Change-control protection.
• Long-term supply capacity.

A second qualified source can have material value because vaginal-ring production depends on consistent extrusion and release performance.

Customized polymer grades

A supplier can develop a polymer grade with a targeted permeability profile rather than sell a standard medical-device resin. Product value increases when the polymer is linked to:

• A defined release-rate window.
• Lower drug adsorption.
• Improved thermal stability.
• Reduced initial burst.
• Better flexibility.
• Lower extractables burden.

The supplier may protect this position through composition, processing, or application patents.

Formulation and process development

Specialized excipient companies can support:

• Active blending.
• Twin-screw or melt extrusion.
• Ring molding.
• In-process uniformity testing.
• Drug-release method development.
• Stability modeling.
• Scale-up from laboratory rings to commercial batches.

This is a higher-margin opportunity than supplying magnesium stearate or generic EVA alone.

Packaging systems

NuvaRing-type products require packaging that protects the polymer and active ingredients from moisture, heat, and light. Opportunities include:

• High-barrier foil pouches.
• Improved resealable packaging.
• Unit-dose packaging.
• Temperature-indicating systems.
• Lower-cost high-throughput packaging.
• Sustainable materials compatible with stability requirements.

Packaging can influence shelf life, shipping conditions, patient convenience, and manufacturing cost.

What generic entry risks exist for NuvaRing-type products?

The main risks are technical and commercial.

Bioequivalence and release matching

A generic ring must demonstrate equivalence through a combination of pharmacokinetic, in-vitro release, and product-quality data. A ring can match total drug content yet fail to match release behavior because of differences in polymer grade, dispersion, surface area, or manufacturing temperature.

Device performance

The ring must maintain flexibility and dimensional integrity during storage and use. Cracking, deformation, excessive stiffness, or drug crystallization can create regulatory and product-liability exposure.

Extractables and leachables

Polymer additives, processing aids, packaging components, and degradation products require assessment. Vaginal administration increases the relevance of local exposure and tissue compatibility.

Commercial price compression

The generic market is exposed to rapid price erosion if several suppliers enter. The strongest commercial position may come from manufacturing reliability, payer access, supply continuity, or a differentiated patient package rather than from a small excipient change.

Regulatory change control

A polymer supplier change can require comparative release testing, stability data, and regulatory filings. A low-cost alternate excipient may have a high switching cost after approval.

Which companies are relevant to the vaginal-ring market?

The competitive landscape includes:

• Organon, associated with the NuvaRing brand and broader women’s-health portfolio.
• Amneal Pharmaceuticals, associated with EluRyng.
• TherapeuticsMD, the original commercial developer of Annovera.
• Mayne Pharma, which acquired U.S. commercial rights to Annovera from TherapeuticsMD.[5]
• The Population Council, which participated in development of segesterone acetate-based contraceptive technology.[4]

The market also includes contract manufacturers, polymer suppliers, packaging companies, and specialty pharmaceutical developers pursuing long-acting contraceptive systems.

How strong is the NuvaRing patent estate?

The original NuvaRing estate has limited remaining exclusivity value compared with a newly launched branded product. Generic approval demonstrates that direct substitution is feasible. The stronger current barriers are:

• Know-how around drug dispersion and extrusion.
• Validated manufacturing processes.
• Stability data.
• Scale-up experience.
• Regulatory comparability packages.
• Supply contracts for qualified polymers.
• Manufacturing capacity for specialized ring equipment.

A new entrant should treat the opportunity as a freedom-to-operate and CMC execution problem, not as a simple excipient substitution exercise. A differentiated ring may obtain new protection through polymer architecture, long-duration release, reusable design, or a distinct drug combination.

What licensing opportunities exist in vaginal-ring technology?

Licensing targets include:

1. Long-duration contraceptive rings.
2. Reusable ring platforms.
3. Biodegradable vaginal devices.
4. Rings delivering noncontraceptive hormones.
5. Rings for HIV prevention or local anti-infective therapy.
6. Platform technologies with independently controlled drug compartments.
7. Proprietary elastomers with validated vaginal compatibility.

The strongest licensing packages combine patents with human tolerability data, validated manufacturing methods, and a qualified excipient supply chain. A polymer patent without manufacturing and regulatory support has lower transaction value.

Key Takeaways

• NuvaRing uses an EVA polymer matrix with magnesium stearate to control release of etonogestrel and ethinyl estradiol.
• The original monthly ring is exposed to generic competition following FDA approval of EluRyng in 2019.
• Commodity EVA supply is a lower-margin opportunity; customized polymer grades and formulation services offer greater strategic value.
• The most defensible innovation areas are longer-duration release, multilayer architecture, reusable designs, biodegradable materials, and improved packaging.
• Annovera confirms that a differentiated ring platform can compete through reduced replacement frequency rather than through direct monthly-ring substitution.
• Generic entry risk centers on release matching, extractables, mechanical integrity, regulatory comparability, and price compression.
• The strongest commercial position is likely to combine proprietary formulation know-how, validated excipients, manufacturing capability, and a credible regulatory pathway.

FAQs About NuvaRing Excipients and Commercial Strategy

Does NuvaRing contain silicone?

The original NuvaRing formulation is based on an ethylene-vinyl acetate copolymer matrix. Silicone is associated more closely with other vaginal-ring technologies, including reusable long-duration systems such as Annovera.

Can a generic manufacturer replace EVA with another polymer?

A manufacturer can develop a different polymer system, but it would need to demonstrate suitable drug release, stability, mechanical performance, local tolerability, and regulatory comparability. The change may create a new product rather than a straightforward generic equivalent.

Is magnesium stearate the main protected excipient in NuvaRing?

No. The central formulation element is the EVA drug-release matrix. Magnesium stearate is a supporting excipient and process aid with less strategic importance than polymer composition, drug loading, and release architecture.

What is the best excipient opportunity for a six-month contraceptive ring?

A rate-controlling polymer or multilayer reservoir system that maintains stable release over six months is the most commercially relevant opportunity. The system must also preserve flexibility, minimize burst release, and support a practical manufacturing process.

Can NuvaRing technology be adapted for noncontraceptive drugs?

Yes. Vaginal rings can deliver hormones, anti-infectives, and other locally or systemically active compounds. The adaptation requires new dose targets, release kinetics, toxicology, tissue-compatibility data, and likely a separate regulatory strategy.

References

1. U.S. Food and Drug Administration. (2024). NuvaRing: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). EluRyng approval letter and prescribing information.
4. U.S. Food and Drug Administration. (2018). Annovera: Prescribing information.
5. Mayne Pharma. (2022). Mayne Pharma acquires U.S. commercial rights for Annovera.